September 21st 2023
In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.
September 15th 2023
Results from the BRUIN study focusing on patients with chronic lymphocytic leukemia/small lymphocytic lymphoma showed benefit in patients were pretreated with Bruton tyrosine kinase inhibitors.
September 8th 2023
Venetoclax has given new hope and better options to a notoriously hard-to-treat patient group.
September 7th 2023
Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
August 28th 2023
Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.
FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL
Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.
The State of the Targeted Therapy Landscape for CLL
In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.
Watch and Wait Remains the Standard in Inactive Early-Stage CLL
A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.
Acalabrutinib Shows Consistent Safety in Older or Frail Patients With CLL
Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.
Matching-Adjusted Indirect Comparison of Acalabrutinib and Zanubrutinib Shows Comparable PFS in R/R CLL
Results presented in a poster at the 2023 ASCO Annual Meeting demonstrated similar progression-free survival between acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia.
Encouraging Responses Observed With Liso-Cel in Relapsed/Refractory CLL/SLL
Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.
Acalabrutinib Plus Obinutuzumab Shows Improved Efficacy in CLL
Susan M. O’Brien, MD, discusses the long-term results of the ELEVATE TN trial in patients with previously untreated chronic lymphocytic leukemia.
Venetoclax and Obinutuzumab With/Without Ibrutinib Improves Efficacy in CLL
Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy
RWE on the Efficacy of Venetoclax-Based Regimens in CLL Match Clinical Trial Data
Real-world evidence support the use of venetoclax-based regimens for patients with chronic lymphocytic leukemia based the consistent efficacy shown between the real-world and clinical trial data.
MURANO: Venetoclax Plus Rituximab in Patients With Relapsed/Refractory CLL
An expert oncologist reviews the MURANO trial of venetoclax plus rituximab in patients with relapsed/refractory CLL and discusses MRD as a parameter of treatment response.
Overview of Treatment Options for Relapsed/Refractory CLL
Catherine C. Coombs, MD, reviews currently available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.
CLL: Prognostic Factors and Treatment Considerations
An expert on chronic lymphocytic leukemia discusses disease progression and prognostic factors that influence treatment decisions.
Patient Profile: A 70-Year-Old Man with Relapsed/Refractory CLL
Catherine C. Coombs, MD, presents the case of a 70-year-old man with relapsed/refractory chronic lymphocytic leukemia and offers her initial impressions.
Treatment Research Landscape in Chronic Lymphocytic Leukemia
John Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.
Clinical Pearls for Treating Patients With Newly Diagnosed CLL
An expert hematologist-oncologist offers advice for community oncologists who are treating patients with newly diagnosed chronic lymphocytic leukemia.
Managing Disease Recurrence in CLL
An overview of assessing risk of disease recurrence, steps taken to minimize recurrence, and when to consider second-line treatment for patients with CLL.
Recent Data from BTK Inhibitor Studies in CLL
An expert on CLL reviews recent data updates from studies of BTK inhibitors in the frontline setting.
CLL Treatment: Managing Adverse Events With Venetoclax and Obinutuzumab
John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.
CLL14: Venetoclax and Obinutuzumab in Patients With Previously Untreated CLL
An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.
MAJIC: Determining the Optimal Frontline Regimen for Previously Untreated CLL
The phase 3 MAJIC study is underway to compare 2 frontline regimens for patients with chronic lymphocytic leukemia.
Frontline Treatment Approaches for Patients With Newly Diagnosed CLL
Risk Stratification for Newly Diagnosed Chronic Lymphocytic Leukemia
An expert hematologist-oncologist discusses the patient case and risk stratification for patients with newly diagnosed CLL.
Case Overview: A 72-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
John Allan, MD, presents the case of a 72-year-old woman with newly diagnosed chronic lymphocytic leukemia and shares his initial impressions.
Antitumor Activity and BTK Degradation Is Observed With NX-2127 in R/R CLL
Acquired resistance to BTK inhibitors is a new and growing challenge in the treatment of CLL and dual resistance to BTK and BCL2 is occurring in more patients, according to Lindsey Roeker, MD.
Awan Discusses the Growing Use of BTK Inhibitors in CLL
AVO Triplet Regimen Continues to Show Durable Responses in High-Risk CLL
The triplet regimen acalabrutinib, venetoclax, and obinutuzumab in the frontline chronic lymphocytic leukemia setting was highly active and well tolerated demonstrating durable responses.
Addressing Unmet Needs for Patients with CLL on Zanubrutinib
Jennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib.
Comparison of BTK Inhibitors Shows Promising Results for Zanubrutinib Over Ibrutinib in CLL/SLL
An interim analysis of the phase 3 ALPINE study showed stronger results for patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma on the next generation BTK inhibitor zanubrutinib than standard of care ibrutinib.
Allan Explores Data on Frontline BTK Inhibition for CLL Treatment
During a Targeted Oncology™ Case-Based Roundtable™ event, John N. Allan, MD, discussed the data supporting the use of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.
Design and Goals of the Phase 3 GLOW Study for CLL
Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia.
2 Clarke Drive Cranbury, NJ 08512